Ramandeep Saini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ramandeep Saini has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Mantosh Kumar Satapathy
Department of Physiology, College of Medicine, Taipei Medical University, No. 250, Wu Hsing St., Taipei 11031, Taiwan
4 shared publications - Ayush Madan
People's University, India
3 shared publications - Bishakha Thakur
Department of Biotechnology, Chandigarh College of Technology, Chandigarh Group of Colleges, Landran, Mohali 140307, Punjab, India
2 shared publications - Bikram Kumar Basaba
Department of Computer Science and Engineering, SRM University-AP, Mangalagiri Mandal, Amaravati 522240, Andhra Pradesh, India
1 shared publication - Megha Bahuguna1 shared publication
- Nainci Dhiman
Chandigarh College of Technology, Chandigarh Group of Colleges, Landran, Greater Mohali 140307, Punjab, India
1 shared publication
Latest Publications
- Open Access
Decoding Biofilm Complexity: Artificial Intelligence, Advanced Imaging, and Multi-Omics for Precision Antibiofilm Strategies
Microbial biofilms are highly structured multicellular communities that exhibit remarkable tolerance to antimicrobial agents and host defenses, contributing to persistent infections, industrial biofouling, food contamination, and environmental challenges. Conventional microbiological approaches have greatly advanced our understanding of biofilm formation but remain insufficient to resolve the spatial, molecular, and functional heterogeneity that underpins biofilm resilience. This review discusses how recent advances in high-resolution imaging, multi-omics technologies, single-cell and spatially resolved analyses, and artificial intelligence (AI) are transforming biofilm research from descriptive observation to precision microbiology. We critically examine state-of-the-art analytical platforms, including confocal and super-resolution microscopy, electron microscopy, Raman-based imaging, genomics, transcriptomics, proteomics, metabolomics, and emerging spatial multi-omics approaches, highlighting their complementary roles in deciphering biofilm architecture, regulatory networks, and metabolic specialization. AI/ML approaches are increasingly being applied to image analysis, multimodal data integration, predictive modeling, biomarker identification, and systems-level interpretation of biofilm biology. Furthermore, we discuss how these technological advances are enabling mechanism-based precision antibiofilm strategies, including extracellular polymeric substance-targeting enzymes, quorum-sensing inhibitors, nanotechnology-enabled therapeutics, bacteriophage-based interventions, and synthetic biology approaches. We highlight the major translational challenges, including data standardization, explainable AI, multimodal integration, benchmark datasets, and clinical validation, and outline future directions for developing clinically relevant, data-driven antibiofilm therapies. This review provides an integrated framework connecting advanced analytical technologies with next-generation precision antibiofilm interventions and offers perspectives for accelerating their translation into clinical and industrial applications.
Open AccessDecoding Biofilm Complexity: Artificial Intelligence, Advanced Imaging, and Multi-Omics for Precision Antibiofilm Strategies
Microbial biofilms are highly structured multicellular communities that exhibit remarkable tolerance to antimicrobial agents and host defenses, contributing to persistent infections, industrial biofouling, food contamination, and environmental challenges. Conventional microbiological approaches have greatly advanced our understanding of biofilm formation but remain insufficient to resolve the spatial, molecular, and functional heterogeneity that underpins biofilm resilience. This review discusses how recent advances in high-resolution imaging, multi-omics technologies, single-cell and spatially resolved analyses, and artificial intelligence (AI) are transforming biofilm research from descriptive observation to precision microbiology. We critically examine state-of-the-art analytical platforms, including confocal and super-resolution microscopy, electron microscopy, Raman-based imaging, genomics, transcriptomics, proteomics, metabolomics, and emerging spatial multi-omics approaches, highlighting their complementary roles in deciphering biofilm architecture, regulatory networks, and metabolic specialization. AI/ML approaches are increasingly being applied to image analysis, multimodal data integration, predictive modeling, biomarker identification, and systems-level interpretation of biofilm biology. Furthermore, we discuss how these technological advances are enabling mechanism-based precision antibiofilm strategies, including extracellular polymeric substance-targeting enzymes, quorum-sensing inhibitors, nanotechnology-enabled therapeutics, bacteriophage-based interventions, and synthetic biology approaches. We highlight the major translational challenges, including data standardization, explainable AI, multimodal integration, benchmark datasets, and clinical validation, and outline future directions for developing clinically relevant, data-driven antibiofilm therapies. This review provides an integrated framework connecting advanced analytical technologies with next-generation precision antibiofilm interventions and offers perspectives for accelerating their translation into clinical and industrial applications.
- 11 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-6
Targeting the Brain: Are Nanodrugs Ready for Clinical Translation in CNS Disorders?
Although significant progress has been made in nanotechnology, the clinical translation of central nervous system (CNS) therapeutics has been limited. While engineered nanocarriers have greatly enhanced blood–brain barrier (BBB) transport, there is now growing evidence that enhanced brain delivery is not sufficient for therapeutic success. Based on this, it is suggested that the key obstacle to translation is now the poor engagement of the molecule at the BBB, its intracellular pharmacology, and its pharmacodynamic response. This perspective underscores the evolving paradigm shift from delivery-based nanomedicine to target-based precision pharmacology where therapeutic engagement is quantified by target occupancy, pathway modulation in the context of disease, and translational relevance to the human condition. This integration of validated disease biology and intelligent delivery design can now be achieved through the advent of new technologies such as artificial intelligence (AI), systems pharmacology, receptor-guided engineering of nanocarriers, spatial multi-omics, brain organoids, and BBB-on-chip technologies. This target-oriented approach is expected to facilitate clinical reproducibility and accelerate the development of safer, more effective, and individualized nanotherapeutics for CNS diseases.
- 11 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-6
Targeting the Brain: Are Nanodrugs Ready for Clinical Translation in CNS Disorders?
Although significant progress has been made in nanotechnology, the clinical translation of central nervous system (CNS) therapeutics has been limited. While engineered nanocarriers have greatly enhanced blood–brain barrier (BBB) transport, there is now growing evidence that enhanced brain delivery is not sufficient for therapeutic success. Based on this, it is suggested that the key obstacle to translation is now the poor engagement of the molecule at the BBB, its intracellular pharmacology, and its pharmacodynamic response. This perspective underscores the evolving paradigm shift from delivery-based nanomedicine to target-based precision pharmacology where therapeutic engagement is quantified by target occupancy, pathway modulation in the context of disease, and translational relevance to the human condition. This integration of validated disease biology and intelligent delivery design can now be achieved through the advent of new technologies such as artificial intelligence (AI), systems pharmacology, receptor-guided engineering of nanocarriers, spatial multi-omics, brain organoids, and BBB-on-chip technologies. This target-oriented approach is expected to facilitate clinical reproducibility and accelerate the development of safer, more effective, and individualized nanotherapeutics for CNS diseases.
- Open Access
Artificial Intelligence–Enabled Organoid Platforms for Precision Medicine: Integrating Multi-Omics, Digital Twins, and Microphysiological Systems
The convergence of artificial intelligence (AI) and organoid technology represents a transformative advance toward precision and predictive medicine. Organoids derived from pluripotent stem cells or patient tissues provide physiologically relevant three-dimensional models that recapitulate key aspects of native organ architecture and function. However, intrinsic biological heterogeneity, high-content imaging outputs, and dynamic spatiotemporal processes pose significant analytical challenges that exceed the capacity of conventional approaches. Recent advances in AI and machine learning enable automated image segmentation, quantitative morphometric profiling, and predictive modeling of organoid growth, differentiation, and therapeutic response, thereby enhancing reproducibility and translational relevance. The integration of multimodal datasets, including imaging, genomics, transcriptomics, epigenomics, proteomics, and metabolomics, has further enabled the development of organoid-based digital twins and in silico disease simulations to optimize personalized therapy. AI-enabled organoid-on-a-chip platforms, cloud-based analytics, and federated learning frameworks are accelerating the emergence of scalable, privacy-preserving, and data-driven biomedical ecosystems. Despite these advances, critical challenges persist, including data standardization, model interpretability, ethical governance, and clinical validation. In contrast to existing reviews that emphasize isolated AI applications, this study proposes a unified translational framework integrating AI-driven image analytics, multi-omics integration, digital twins, and organoid-on-a-chip systems within a precision medicine paradigm. By synthesizing current developments, methodological advances, and emerging trends, this study highlights how AI-powered organoid platforms can bridge experimental biology and clinical decision-making, with broad implications for drug discovery, disease modeling, and regenerative medicine. This review aims to provide a comprehensive overview of artificial intelligence–enabled organoid platforms by integrating advances in image analytics, multi-omics data integration, digital twins, and microphysiological systems, while highlighting their potential applications and future directions in precision medicine, drug discovery, and regenerative healthcare.
Open AccessArtificial Intelligence–Enabled Organoid Platforms for Precision Medicine: Integrating Multi-Omics, Digital Twins, and Microphysiological Systems
The convergence of artificial intelligence (AI) and organoid technology represents a transformative advance toward precision and predictive medicine. Organoids derived from pluripotent stem cells or patient tissues provide physiologically relevant three-dimensional models that recapitulate key aspects of native organ architecture and function. However, intrinsic biological heterogeneity, high-content imaging outputs, and dynamic spatiotemporal processes pose significant analytical challenges that exceed the capacity of conventional approaches. Recent advances in AI and machine learning enable automated image segmentation, quantitative morphometric profiling, and predictive modeling of organoid growth, differentiation, and therapeutic response, thereby enhancing reproducibility and translational relevance. The integration of multimodal datasets, including imaging, genomics, transcriptomics, epigenomics, proteomics, and metabolomics, has further enabled the development of organoid-based digital twins and in silico disease simulations to optimize personalized therapy. AI-enabled organoid-on-a-chip platforms, cloud-based analytics, and federated learning frameworks are accelerating the emergence of scalable, privacy-preserving, and data-driven biomedical ecosystems. Despite these advances, critical challenges persist, including data standardization, model interpretability, ethical governance, and clinical validation. In contrast to existing reviews that emphasize isolated AI applications, this study proposes a unified translational framework integrating AI-driven image analytics, multi-omics integration, digital twins, and organoid-on-a-chip systems within a precision medicine paradigm. By synthesizing current developments, methodological advances, and emerging trends, this study highlights how AI-powered organoid platforms can bridge experimental biology and clinical decision-making, with broad implications for drug discovery, disease modeling, and regenerative medicine. This review aims to provide a comprehensive overview of artificial intelligence–enabled organoid platforms by integrating advances in image analytics, multi-omics data integration, digital twins, and microphysiological systems, while highlighting their potential applications and future directions in precision medicine, drug discovery, and regenerative healthcare.
- 13 April 2026
- Published by Taylor & Francis
- p. 36-55
Mechanism of Neurodegeneration in Alzheimer's Disease
- 13 April 2026
- Published by Taylor & Francis
- p. 36-55
Mechanism of Neurodegeneration in Alzheimer's Disease
- Open Access
Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions
Organoid technology has emerged as a revolutionary tool in cancer research, offering physiologically accurate, three-dimensional models that preserve the histoarchitecture, genetic stability, and phenotypic complexity of primary tumors. These self-organizing structures, derived from adult stem cells, induced pluripotent stem cells, or patient tumor biopsies, recapitulate critical aspects of tumor heterogeneity, clonal evolution, and microenvironmental interactions. Organoids serve as powerful systems for modeling tumor progression, assessing drug sensitivity and resistance, and guiding precision oncology strategies. Recent innovations have extended organoid capabilities beyond static culture systems. Integration with microfluidic organoid-on-chip platforms, high-throughput CRISPR-based functional genomics, and AI-driven phenotypic analytics has enhanced mechanistic insight and translational relevance. Co-culture systems incorporating immune, stromal, and endothelial components now permit dynamic modeling of tumor–host interactions, immunotherapeutic responses, and metastatic behavior. Comparative analyses with conventional platforms, 2D monolayers, spheroids, and patient-derived xenografts emphasize the superior fidelity and clinical potential of organoids. Despite these advances, several challenges remain, such as protocol variability, incomplete recapitulation of systemic physiology, and limitations in scalability, standardization, and regulatory alignment. Addressing these gaps with unified workflows, synthetic matrices, vascularized and innervated co-cultures, and GMP-compliant manufacturing will be crucial for clinical integration. Proactive engagement with regulatory frameworks and ethical guidelines will be pivotal to ensuring safe, responsible, and equitable clinical translation. With the convergence of bioengineering, multi-omics, and computational modeling, organoids are poised to become indispensable tools in next-generation oncology, driving mechanistic discovery, predictive diagnostics, and personalized therapy optimization.
Open AccessOrganoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions
Organoid technology has emerged as a revolutionary tool in cancer research, offering physiologically accurate, three-dimensional models that preserve the histoarchitecture, genetic stability, and phenotypic complexity of primary tumors. These self-organizing structures, derived from adult stem cells, induced pluripotent stem cells, or patient tumor biopsies, recapitulate critical aspects of tumor heterogeneity, clonal evolution, and microenvironmental interactions. Organoids serve as powerful systems for modeling tumor progression, assessing drug sensitivity and resistance, and guiding precision oncology strategies. Recent innovations have extended organoid capabilities beyond static culture systems. Integration with microfluidic organoid-on-chip platforms, high-throughput CRISPR-based functional genomics, and AI-driven phenotypic analytics has enhanced mechanistic insight and translational relevance. Co-culture systems incorporating immune, stromal, and endothelial components now permit dynamic modeling of tumor–host interactions, immunotherapeutic responses, and metastatic behavior. Comparative analyses with conventional platforms, 2D monolayers, spheroids, and patient-derived xenografts emphasize the superior fidelity and clinical potential of organoids. Despite these advances, several challenges remain, such as protocol variability, incomplete recapitulation of systemic physiology, and limitations in scalability, standardization, and regulatory alignment. Addressing these gaps with unified workflows, synthetic matrices, vascularized and innervated co-cultures, and GMP-compliant manufacturing will be crucial for clinical integration. Proactive engagement with regulatory frameworks and ethical guidelines will be pivotal to ensuring safe, responsible, and equitable clinical translation. With the convergence of bioengineering, multi-omics, and computational modeling, organoids are poised to become indispensable tools in next-generation oncology, driving mechanistic discovery, predictive diagnostics, and personalized therapy optimization.